We analyzed a complex chromosomal translocation in a case of embryonal rhabdomyosarcoma (RMS) and showed that it generates the fusion gene PAX3 (paired box 3)-NCOA2 (nuclear receptor coactivator 2). To understand the role of this translocation in RMS tumorigenesis, we established two types of stable mouse myoblast C2C12 cell lines expressing PAX3-NCOA2 and PAX3-FOXO1A (forkhead box O1A), respectively. Compared with control cells, PAX3-NCOA2 cells grew faster, were more motile, were less anchorage dependent, progressed more quickly through the G1/S phase of cell cycle and showed greater transcriptional activation of the PAX3 consensus-binding site. However, PAX3-NCOA2 cells proliferated more slowly and differentiated more weakly than did PAX3-FOXO1A cells. Both PAX3-NCOA2 cells and PAX3-FOXO1A cells formed tumors in nude mice, although the PAX3-NCOA2-induced tumors grew more slowly. Our results may explain why NCOA2 rearrangement is mainly found in embryonal rhabdomyosarcoma, which has a better prognosis than alveolar rhabdomyosarcoma, which expresses the PAX3-FOXO1A fusion gene. These results indicate that the PAX3-NCOA2 fusion gene has a dual role in the tumorigenesis of RMS: promotion of the proliferation and inhibition of the myogenic differentiation of RMS cells.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue tumor. RMS can be divided into two main histopathological subgroups: embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). These subgroups differ considerably in their clinical phenotype and molecular features. The prognosis of ERMS is more favorable than that of ARMS. The majority of cases of the more aggressive ARMS are associated with one of two reciprocal translocations: t(2;13)(q35;q14), which generates an intronic fusion of PAX3 (paired box 3) and FOXOA1 (forkhead box O1A) that is also known as FKHR (forkhead in human rhabdomyosarcoma) and t(1;13)(p36;q14), which generates an intronic fusion of PAX7 and FOXOA1.
1 The PAX3-FOXO1A translocation is associated with increased treatment failure and mortality rate. 2 PAX family members are transcription factors that regulate pattern formation during embryogenesis. 3 Several PAX genes, including PAX3 and PAX7, contribute to tumorigenesis. 4 Pax3 is expressed in the developing nervous system and in somite compartments that give rise to skeletal muscle progenitors. 5, 6 Exons 2, 3 and 4 of PAX3 encode the paired box, which is a distinctive feature of the PAX family, whereas the homeodomain is encoded by exons 5 and 6, and functions as a DNA-binding domain. Forkhead box (or FOX) genes have diverse roles including control of embryonic development and adult tissue-specific gene expression. FOXO1A has one transactivation domain (TAD) at the C-terminus, 7 and translocations between PAX3 and FOXO1A lead to an increase in transcriptional activation of the DNA-binding domains on PAX3. PAX3-FOXO1A induces cellular proliferation 8 and malignant transformation 9 and suppresses apoptosis. 10 Recurrent NCOA2 (nuclear receptor coactivator 2) gene rearrangements occur in ERMS. 11, 12 Mosquera et al. 11 reported NCOA2 gene rearrangements (SRF-NCOA2 and TEAD1-NCOA2) in three cases of spindle cell RMS. Sumegi et al. 12 identified the fusion gene PAX3-NCOA2 in each case of ERMS and ARMS that they investigated. We previously found a translocation involving chromosome band 2q35, which is the locus of the PAX3 gene. 13 We later identified NCOA2 as a candidate PAX3 partner gene using fluorescence in situ hybridization (FISH). NCOA2 belongs to the p160 protein family, which also includes SRC-1 (steroid receptor coactivator), NCOA2/TIF2/ GRIP1/SRC-2 and pCIP/ACTR/AIB-1/RAC-3/TRAM-1/ SRC-3. NCOA2 has several functional domains including a PAS (sequence similarity with the Per Arndt-Sim motifs)/bHLH (sequence similarity with basic helix-loop-helix motifs) domain, a receptor interaction region, and two TADs.
14-17 NCOA2 is necessary for myogenic differentiation. 17 In nuclear receptor signaling, NCOA2 binds to nuclear receptors predominantly through its nuclear receptor-interacting domain (NID) 18, 19 and recruits two transcriptional co-activators, CBP (CREB-binding protein)/p300 and CARM-1. CBP/p300 is recruited through its CBP interaction domain (CID/TAD1) 16, 20 and CARM-1, an arginine methyltransferase, is recruited through TAD2. [21] [22] [23] [24] Sumegi et al. 12 demonstrated that deletion of TAD1 from PAX3-NCOA2 more strongly suppressed the transforming activity of the chimeric protein than did deletion of TAD2, and PAX3-NCOA2 needed an intact activation domain 2(TAD2) and CID for optimal transforming activity using the NIH3T3 mouse fibroblast cell line. Both TADs on NCOA2 boost transcriptional activation of PAX3-NCOA2, as they do in PAX3-FOXO1A. However, the role of the NCOA2 rearrangement including PAX3-NCOA2 in RMS tumorigenesis remains to be elucidated. In this study, we compared the biological function of the PAX3-NCOA2 fusion protein with PAX3-FOXO1A fusion protein to reveal the function of PAX3-NCOA2 in RMS tumorigenesis both in vitro and in vivo. To this end, we expressed these two fusion genes in C2C12 mouse myoblast cell lines and studied their biological character. RESULTS PAX3-NCOA2 was identified in an ERMS tumor specimen and transcriptional activation of the PAX3 consensus-binding site was enhanced We previously showed the PAX3 rearrangement in our case with ERMS by FISH analysis. 13 To identify the partner gene of PAX3 in this case with the complex translocation involving 2q35 and 8q13, and so on, we narrowed down the 8q13 breakpoint region by stepwise FISH approach using bacterial artificial chromosome (BAC) probes located on chromosome 8q13. The results demonstrated that the BAC clone RP11-479K21 (located at 8q13.3) spanned the 8q13 breakpoint, and that the split signal of RP11-479K21 probe was fused to the signal of RP11-624P23 (on the telomeric side of the PAX3 gene located at 2q35) (data not shown). RP11-479K21 clone contained the NCOA2 gene. These results suggested that the candidate partner gene of PAX3 was NCOA2 in our case with ERMS. Sequence analysis of the PAX3-NCOA2 PCR products of our patient's sample revealed that exon 7 of PAX3 (391st AA) was fused to exon 12 (798th AA) of the NCOA2 gene in-frame (Figure 1a) . The resulting PAX3-NCOA2 fusion protein consisted of the 391 N-terminal AA of PAX3 and the 666 C-terminal AA of NCOA2. A schema of the structures of intact and chimeric proteins is shown in Figure 1b . The PAX3-NCOA2 fusion gene retained the DNA-binding domain of PAX3, and the CID/ TAD1 and TAD2 domains of NCOA2, in agreement with the findings of Sumegi et al. 12 When HEK293 cells were transfected with the GFP-PAX3-NCOA2 expression vector, PAX3-NCOA2 localized in the nucleus (Figures 2a and b) . The expressions of PAX3-NCOA2 enhanced transcriptional activation of the PAX3 consensus-binding site 3.8 times more than did the expression of the wild-type PAX3 and the expression of PAX3-FOXO1A enhanced it 19.8 times more (both Po0.05) (Figure 2c ).
PAX3-NCOA2 stimulated proliferation and motility in myoblasts in vitro
We confirmed the protein expressions of PAX3-NCOA2 and PAX3-FOXO1A in HEK293 cells transiently transfected with FLAG-tagged constructs by western blotting (Figure 3a) . Cell proliferation was assessed using C2C12 cells expressing PAX3-NCOA2, PAX3-FOXO1A or MSCV empty vector. On day 4, the numbers of PAX3-NCOA2 C2C12 cells and PAX3-FOXO1A C2C12 cells were 1.3 times more (Po0.05) and 1.7 times more (Po0.05), respectively, than the number of control cells (Figure 3b ). The PAX3-NCOA2 cells switched from the G1phase to the S phase and showed an accelerated cell cycle progression (Figure 3c ). Wound closure was more rapid with both the PAX3-NCOA2 cells and PAX3-FOXO1A cells than with the control cells (Figure 3d ), indicating that the transformed cells have an enhanced motility. However, the wound width (% of original width) indicated that the PAX3-NCOA2 cells were not as motile as the PAX3-FOXO1A cells. When the cells were plated on soft agar, 3 ± 0.5 colonies grew from the control cells, whereas 53.6±4.2 and 115.2±0.5 colonies grew from the PAX3-NCOA2 cells and PAX3-FOXO1A cells (Figure 3f ), respectively, indicating that both lines were capable of anchorage-independent growth. However, anchorage-independent growth of the PAX3-NCOA2 cells was only about half that of the PAX3-FOXO1A cells (Figure 3g ). PAX3-NCOA2 inhibited the differentiation from myoblasts into myotubes in the differentiation medium PAX3-NCOA2 and PAX3-FOXO1A morphologically blocked myotube differentiation (Figure 4a ). Few of either PAX3-NCOA2 
PAX3-NCOA2 promoted tumorigenesis in vivo
When fibroblasts expressing the fusion genes were transplanted into nude mice, the PAX3-NCOA2 and PAX3-FOXO1A cells took B6.8 and 5.2 weeks, respectively, to form 15-mm-diameter tumors ( Figure 5a ). Therefore, tumorigenic properties of the PAX3-NCOA2 and PAX3-FOXO1A cell lines well reflect their in vitro anchorage-independent growth.
Every tumor was solid, firm and fibrotic. Unexpectedly, the tumors induced by the PAX3-NCOA2 and PAX3-FOXO1A cells did not differ with respect to any of eight characteristics examined: cell shapes, growth pattern/architecture, cellular cohesiveness, muscle differentiation, number of giant cells, nuclear-to-cytoplasm volume ratio reversal, hyperchromatism, cellular/nuclear pleomophism and stromal matrix. None of the tumors displayed the alveolar architectures on H&E stain and silver impregnation ( The LXXLL motifs of PAX3-NCOA2 was not required for anchorageindependent growth The LXXLL motif (where L is leucine and X is any amino acid) is found in various co-activators, including NCOA 25, 26 and FOXO family proteins, as well as in PAX3-NCOA2 and PAX3-FOXO1A (Figure 1b) . To examine whether the LXXLL motif is involved in anchorage-independent growth, we constructed mutation/deletion constructs of the motif (Supplementary Table 1 ) following previous reports. 27, 28 However, these mutations and deletions did not significantly affect anchorage-independent growth of either cell line (Figure 6 ), suggesting that the LXXLL motif is not a promising therapeutic target.
DISCUSSION
Our in vitro results revealed that the expression of PAX3-NCOA2 promoted transcriptional activation of the PAX3 consensusbinding site and that PAX3-NCOA2 actually acted as a transcriptional activator. PAX3-NCOA2 also enhanced proliferation, cell cycle progression, motility and anchorage-independent growth. In addition, we showed that PAX3-NCOA2 blocked myotube differentiation. These data indicated that PAX3-NCOA2 has a dual role in the tumorigenesis of RMS: promotion of cell proliferation and inhibition of myogenic differentiation. Our PAX3-NCOA2 results bear a close resemblance to previous findings that PAX3-FOXO1A promoted cell proliferation and motility and inhibited differentiation. [29] [30] [31] Our results suggest that PAX3-NCOA2 and PAX3-FOXO1A share the same mechanism for tumorigenesis. Finckenstein et al. 32 called PAX3-FOXO1A genes 'pangenes' in tumorigenesis, meaning that they simultaneously initiate myogenesis and inhibit terminal differentiation. It is not surprising that PAX3-NCOA2 acts as a pangene like PAX3-FOXO1A because PAX3-NCOA2 induces tumors derived from muscle tissue in vivo.
The tumors in nude mice derived from C2C12 cells transformed with PAX3-NCOA2 share several pathologic features with human ERMS tumor samples: the shapes of cells were small and round or spindle-like, and the cells having abundant cytoplasm were irregularly distributed among immature undifferentiated cells (Figure 5b , i-vi). Although PAX3-FOXO1A-expressing C2C12 cells developed non-invasive ERMS-like tumors in our experiment, Zhang et al. 33 showed that mouse myoblasts transformed with PAX3-FOXO1A-induced malignant, ARMS-like tumors in mice. In addition, almost all PAX3-FOXO1A tumor-bearing mice develop spontaneous metastasis to the lungs, one of the targeted sites for metastasis in human ARMS. On the other hand, Wang et al. 34 reported that a PAX3-FOXO1A stable cell line formed tumors but the tumors did not have alveolar structure and did not invade any organ, in agreement with our results. As suggested by Naini et al. 35 , whether or not a tumor is malignant with alveolar structure may depend on not only PAX3-FOXO1A but also one or more other abnormalities as well, loss of p16INK4A/p14ARF or overexpression of MYCN.
Sumegi et al. 12 did not report the prognosis of his patients with the PAX3-NCOA2 fusion gene. However, our case had localized RMS, responded to standard therapy and is alive and in remission at 9 years after treatment. Mosquera et al.
11 also reported recurrent NCOA2 rearrangements in spindle cell-type RMS, which is a subtype with good prognosis. In all of our experiments, the most aggressive phenotype was PAX3-FOXO1A, followed by PAX3-NCOA2, as expected. The finding that the PAX3-NCOA2 stable cell line expressed a less aggressive phenotype than did the PAX3-FOXO1A stable cell line supports our hypothesis that RMS with the PAX3-NCOA2 fusion gene has a better prognosis than RMS with the PAX3-FOXO1A fusion gene.
The LXXLL motif was originally observed in cofactor proteins that interact with hormone-activated nuclear receptors. Functionally active examples of LXXLL motifs have also been documented in proteins that do not directly interact with nuclear receptors, including several transcription factors, 36, 37 cAMP (cyclic adenosine monophosphate) response element-binding protein (CREB)-binding protein (CBP) and p300, 38 and mediator subunits. In fact, PAX3-NCOA2 has two LXXLL motifs. Deguchi et al. 28 constructed LXXLL mutants and deletions of MOZ-TIF2 fusion protein, and demonstrated that these abnormalities contributed to decrease anchorage-independent growth and transcriptional activity in murine bone marrow cells. On the other hand, PAX3-FOXO1A has only one LXXLL motif. Mutating it was found to decrease the transcriptional activity of FOXO1A in simian virus-40-transformed hepatocytes. 27 However the LXXLL motif did not have a key role in our experimental system using a mouse myoblast cell line transduced with human chimeric genes. This difference might be due to a difference of cell types or to a difference in the conformation of the chimeric proteins.
In conclusion, our study has two main findings: the PAX3-NCOA2 fusion gene 1) has a dual role in the tumorigenesis of RMS, promoting cell proliferation and inhibiting myogenic differentiation and 2) is less aggressive than the PAX3-FOXO1A fusion gene. PAX3-NCOA2 could be a potential marker of low risk in RMS. The analyses needed to determine the risk stratification and prognostic factors of RMS have progressed from classic morphology to molecular diagnoses, using aberrant chimeric genes. The present results should help provide a more rational stratification of RMS.
MATERIALS AND METHODS

Tumor tissue samples
Tumor specimens from our patient with ERMS were surgically resected before any chemotherapy and immediately stored at À 80 1C. The patient's symptoms are described elsewhere. 13 Written informed consent was given by the parents according to the protocol approved by the institutional 
FISH analysis
The BAC clones (RP11 series) were selected according to the University of California Santa Cruz Genome Browser (http://genome.ucsc.edu) and were obtained from Invitrogen (Basel, Switzerland). These BAC DNAs were isolated using a NucleoBond BAC 100 kit (Macherey-Nagel Inc., Easton, PA, USA) and were directly labeled by means of nick translation with SpectrumGreen-dUTP or SpectrumOrange-dUTP (Abbott Molecular/Vysis, Des Plaines, IL, USA). Hybridization, washing and detection were performed using standard procedures. FISH images were captured and analyzed with the PowerGene system (Applied Imaging, Santa Clara, CA, USA).
Cell cultures, transfection, infection and reagents
Mouse myoblast C2C12 cells and human embryonic kidney HEK293 were purchased from the American Type Culture Collection (Manassas, VA, USA). These cells were maintained in growth medium: Dulbecco's modified Eagle's high-glucose medium, supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (10 mg/ml) at 37 1C in a humidified atmosphere of 5% CO 2 . Stable C2C12 cell lines expressing PAX3-NCOA2, and PAX3-FOXO1A were established using a murine stem cell virus (MSCV) retrovirus expression system (Clontech Laboratories Inc., Madison, WI, USA). C2C12 cells were transfected in 60-mm dishes at B50% confluence with 1 mg of purified expression vector DNA, 8 ml of Enhancer and 7.5 ml of Effectene (Qiagen, Hombrechtikon, Switzerland) in 1 ml of Dulbecco's modified Eagle's high-glucose medium. After 48 h, the cells were trypsinized and replanted at a 1: 5 dilution in medium. Selection of stability transfected cells was performed with 1000 mg/ml of G418 sulfate (Life Technologies, Carlsbad, CA, USA). A dual role of PAX3-NCOA2 in rhabdomyosarcoma H Yoshida et al iodide fluorescence was read on a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA), and the data were analyzed with Cell Quest software (BD Biosciences). The cell cycle phase was determined on the basis of DNA content using the ModFit LT Software (Verity Software House, Topsham, ME, USA) as described previously. 39 Anchorage-independent soft agar colony formation assay Cells were cultured in a two-layer soft agar system developed by Hambruger et al. 40 It consisted of a 1% Noble agar underlayer and a 0.7% Noble agar overlayer containing 2 Â 10 4 cells in 35-mm dishes. Colonies were allowed to form for duration of 2 weeks with fresh media added every 3 days. Plates were stained with crystal violet and colonies more than 0.1 mm in diameter were counted.
Luciferase reporter assay for PAX3-FOXO1A enhancer A luciferase reporter construct was generated by inserting multimerized PAX3 DNA-binding sites (6 Â e5 DNA-binding sites) into pGL3 vector. A total of 1 Â 10 5 HEK293 cells were plated per 35-mm plate and cotransfected 24 h later with FLAG expression vectors, pGL3 basic 6 Â e5 vector and pRL-TK vector; 290, 90 and 20 mg, respectively. Luciferase activity was determined by using a dual luciferase assay system (Promega, Wallisellen, Switzerland) to adjust for differences in transfection efficiency. Data shows luciferase expression relative to pFLAG wild-type PAX3.
Western blot
Cells were lysed with Laemmli sample buffer. Protein concentrations in the cell lysates were measured with the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Samples were boiled for 5 min in sample buffer containing bromophenol blue and 1 Â b-ME, and equal amounts of protein were separated by sodium dodecylsulfate-polyaclylamide gel electrophoresis (SDS-PAGE). Electrophoretic separation was carried out on 10% polyacrylamide gel (Bio-Rad Laboratories), and the proteins were subsequently transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA). Membranes were blocked in PBST (phosphate-buffered saline with Tween 20) with 5% non-fat dry milk powder and incubated with the following primary antibodies: FLAG (Sigma-Aldrich, St Louis, MO, USA). The membranes were then washed with PBST and incubated with goat antimouse secondary antibody (GE Healthcare, Little Chalfont, UK) or antirabbit (GE Healthcare). Antibody binding was detected with the enhanced chemiluminescence detection system (ECL and ECL plus; GE Healthcare).
Assays for the differentiation of myoblast and immunofluorescence
To initiate myogenesis, cells were rinsed thoroughly with phosphatebuffered saline (PBS) before adding differentiation medium; Dulbecco's modified Eagle's high-glucose medium containing 2% Horse serum, penicillin (100 U/ml), and streptomycin (10 mg/ml) 24 h after seeding (day 1). Differentiated cells were observed on day 4 with a confocal microscope BZ-8000 (KEYENCE) to assess morphological change. For immunofluorescence, cells on cover slips were fixed with absolute , silver impregnation (iii) and with antibodies specific for desmin (iv), myoD1 (v) and myogenin (vi). Scale bar, 200 mm (i, iii) and 100 mm (ii, iv-vi), respectively. The tumor cells ranged from small round cells to large elongated poorly differentiated cells, and exhibited varying degrees of myogenic differentiation. There were small oval or long spindle-shaped differentiated rhabdomyoblasts with eosinophilic cytoplasm, without cross striation. Even in silver impregnation (iii), there was no alveolar architecture. Also lacking was the classic cystic pattern with tumor cells palisaded against fibrovascular stroma. None of the cells were anaplastic. In the immunohistology, desmin, myoD1 and myogenin were positive; however, the expressions of myoD1 and myogenin were different. Thus, the latter differentiation in rhabdomyogenesis appeared to be abnormal or suppressed. Figure 6 . Effect of mutations and deletions of the LXXLL motif on anchorage-independent growth of PAX3-NCOA2 and PAX3-FOXO1A cells using a colony-forming soft agar assay. Results represent the means±s.d. of three independent experiments. A P-value of less than 0.05 was considered statistically significant; NS, no significance.
methanol, washed and incubated with anti-myosin heavy chain antibody (Sigma-Aldrich) for 1 h, rinsed with PBS, incubated with fluorescein isothiocyanate-conjugated anti-mouse IgG (Invitrogen) for 1 h, and visualized using a fluorescence microscope as previously described. 41 Wound-healing assay
The cell layers were scratched using a pipette tip, and then cultured in the differentiation medium. Immediately after scratching (0 h), the plates were photographed and the distance between the edges of the wound area was measured and defined as 100%. At 6 h after scratching, the plates were photographed and the distance between the edges of the wound region was again measured and presented as a percentage of the distance between the edges of wound area at 0 h.
In vivo tumorigenesis
Tumors were induced in 4-to 6-week-old male athymic nude mice (BALB/c nu/nu; SHIMIZU Laboratory Supplies, Kyoto, Japan). Each mouse was injected subcutaneously with 2 Â 10 6 C2C12 cells suspended in 0.5 ml of PBS at a single site to the lower flank. Tumor diameter was monitored every 2 or 3 days on onset of tumor formation. Mice were killed when the tumor size reached 17 mm in diameter. At the end point of the experiments, tumors were extracted and immediately photographed. A portion of the tumor was embedded in paraffin for histopathological and immunohistochemical analyses. At least three mice were used in each experiment. The mice used for this study were handled in strict adherence with local governmental and institutional animal care regulation.
Histopathology and immunohistochemistry
Histological specimens were fixed in 10% formalin and routinely processed for embedding in paraffin. Histological sections 4-mm-thick were stained with hematoxylin and eosin (H&E), silver impregnation or hybridized to antibodies specific for desmine, myoD1 and myogenin. Slides were reviewed by a board-certified pathologist (H Hojo) to define the histologic type of cancer. The sections were incubated with anti-desmin, anti-myoD1 and anti-myogenin antibody that was diluted at 1:20, 1:25 and 1:50 respectively. Sections were then treated with a VECTASTAIN Elite ABC kit (Vector Laboratories, Burlingame, CA, USA).
Mutant and deletion construction
The LXXLL motif of NCOA2 was mutagenized by inverse PCR using Topo-PAX3-NCOA2-vector with XhoI and Bam HI tags as a template. The PCRs were initiated with a 2-min incubation at 95 1C followed by 10 cycles of 95 1C for 30 s, 60 1C for 30 s and 72 1C for 7 min, and finally 10 min incubation at 72 1C. The template plasmid was digested with Dpn I for 1 h at 37 1C, and the remaining PCR products were treated with restriction enzymes XhoI and Bam HI. A total of 7.5 ml MSCV vector and insert DNA with 7.5 ml Ligation high ver.2 were ligated with a DNA Ligation Kit Ligation high Ver.2 (Toyobo, Osaka, Japan) according to the manufacturer's instructions. Thereafter, the composed plasmid was transformed into competent cells, and MSCV vector containing these cDNAs was generated by transfecting C2C12 cells. Mutagenesis/deletion of the LXXLL motifs of PAX3-NCOA2 and PAX3-FOXO1A were performed in the same way. The primer pairs used in this study are listed in Supplementary Table 2 .
Statistical analysis
Statistical analysis was performed using the unpaired Student's t-test. A P-value of less than 0.05 was considered statistically significant. ABBREVIATIONS ARMS, alveolar rhabdomyosarcoma; BAC, bacterial artificial chromosome; bHLH, sequence similarity with basic helix-loophelix motifs; CBP, CREB-binding protein; cDNA, complementary DNA; CID, CBP interaction domain; CREB, cAMP (cyclic adenosine monophosphate) response element-binding protein; DM, differentiation medium; ERMS, embryonal rhabdomyosarcoma; FISH, fluorescence in situ hybridization; FKHR, forkhead in human rhabdomyosarcoma; FOXO1A, forkhead box O1A; G1, Gap1; GFP, green fluorescent protein; H&E, hematoxylin and eosin; LXD, LXXLL-containing helical motif; MHC, myosin heavy chain; MSCV, murine stem cell virus; NCOA2, nuclear receptor coactivator 2; NID, nuclear receptor-interacting domain; PAS, sequence similarity with the Per Arndt-Sim (PAS) motifs; PAX3, paired box 3; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline with Tween 20; PI, propidium iodide; RMS, rhabdomyosarcoma; RT-PCR, reverse transcription-polymerase chain reaction; SDS-PAGE, sodium dodecylsulfate-polyacrylamidegel electrophoresis; TAD, transactivation domain
